肿瘤溶解综合征成人早期拉布立酶治疗与肾脏替代治疗及死亡风险
该研究采用模拟目标试验设计,纳入36家美国医院2014—2023年1276例成人TLS患者,比较TLS起病12小时内接受拉布立酶与未接受者的结局。早期拉布立酶组肾脏替代治疗或死亡复合终点发生率为32.7%,对照组为42.0%,校正OR 0.67(95%CI 0.52–0.88)。90天死亡校正OR为0.71(95%CI 0.54–0.94)。结果提示TLS成人早期拉布立酶治疗与肾脏替代治疗或死亡风险降低相关。
要点
- TLS成人起病12小时内接受拉布立酶者肾脏替代治疗或死亡复合终点32.7%,未接受者为42.0%。
- 校正混杂后早期拉布立酶与复合终点风险降低相关:aOR 0.67(95%CI 0.52–0.88;P<0.001)。
- 90天死亡同样获益:aOR 0.71(95%CI 0.54–0.94)。
- 接受拉布立酶者尿酸更高(中位0.71 vs 0.59 mmol/L),但加权后病情严重度均衡。
- 早期治疗组给药中位时间为TLS起病后5.0小时(IQR 3.1–7.5小时)。
适用人群与场景
- 纳入36家美国医院2014—2023年收治的1276例成人(≥18岁),均有活动性血液恶性肿瘤或实体瘤转移、高肿瘤负荷,或实验室与临床特征符合TLS。
- 排除标准原文未提及。
诊断标准与关键阈值
- TLS诊断依据原文描述为「laboratory findings and clinical features consistent with TLS」,具体实验室界值原文未提及。
- 早期治疗定义为TLS起病后12小时内给予拉布立酶。
处置流程与药物剂量
- 对符合TLS的成人,在TLS起病12小时内给予拉布立酶;原文未提及具体剂量、给药途径、频次或疗程。
- 原文未提及降尿酸目标值或其他辅助治疗措施。
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 研究类型为模拟目标试验(emulated target trial),36家美国医院,1276例成人TLS患者。
- 干预:TLS起病12小时内接受拉布立酶(705例,55.3%);对照:未在12小时内接受拉布立酶。
- 主要终点为指数住院期间肾脏替代治疗或死亡复合终点:32.7% vs 42.0%,校正OR 0.67(95%CI 0.52–0.88;P<0.001)。
- 关键次要终点90天死亡:校正OR 0.71(95%CI 0.54–0.94)。
- 接受拉布立酶者基线尿酸更高(中位0.71 vs 0.59 mmol/L,即11.9 vs 9.9 mg/dL),经逆概率治疗加权后病情严重度均衡;多项敏感性分析结果一致。
证据类型、等级与局限
- 证据类型:模拟目标试验(观察性数据模拟随机试验),非RCT。
- 局限性:原文未明确列出;设计上属观察性模拟试验,存在未测量混杂可能。
对床旁实践的改变
- 对符合TLS的成人,可考虑在起病12小时内启动拉布立酶以降低肾脏替代治疗或死亡风险;具体剂量与疗程需参照药品说明书,原文未提供。
- 不应将本研究的关联性结果等同于RCT证实的因果效应;原文未提及不适用人群。
指南或共识出处
- 原文未提及指南或共识名称;研究发表于BMJ。
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: To examine the association between early rasburicase treatment and acute kidney injury requiring kidney replacement therapy or death among patients with tumour lysis syndrome (TLS).
DESIGN: Emulated target trial.
SETTING: 36 US hospitals.
PARTICIPANTS: 1276 adults (≥18 years) admitted to hospital between 2014 and 2023 with active haematological malignancy or solid tumour with metastases, high tumour burden, or laboratory findings and clinical features consistent with TLS.
MAIN OUTCOME MEASURES: The primary outcome was a composite of acute kidney injury requiring kidney replacement therapy or death during the index hospital admission. A key secondary outcome was 90 day mortality. Outcomes were compared between patients who received rasburicase within 12 hours after TLS onset and those who did not, using logistic regression with inverse probability of treatment weighting to adjust for confounding.
RESULTS: Among 1276 patients included in the analysis, 705 (55.3%) received rasburicase within 12 hours after TLS onset. Among patients treated within 12 hours of TLS onset, rasburicase was administered at a median of 5.0 hours (interquartile range 3.1-7.5 hours). Patients who received rasburicase had higher uric acid concentrations than those who did not (median 0.71 v 0.59 mmol/L (11.9 v 9.9 mg/dL)); however, severity of illness was well balanced after applying inverse probability of treatment weighting. Early rasburicase treatment was associated with a lower risk of acute kidney injury requiring kidney replacement therapy or death (32.7% v 42.0%; adjusted odds ratio 0.67, 95% confidence interval 0.52 to 0.88; P<0.001). Results were consistent across multiple sensitivity analyses and for 90 day mortality (adjusted odds ratio 0.71, 0.54 to 0.94).
CONCLUSIONS: Among adults with TLS, early rasburicase treatment for TLS was associated with about one third lower risk of acute kidney injury requiring kidney replacement therapy or death compared with delayed or no rasburicase treatment.
参考来源
- Shenoy T, Sanchez-Almanzar D, Dias JA, et al. Early treatment with rasburicase and risk of kidney replacement therapy and death in adults with tumour lysis syndrome: emulated target trial. BMJ. 2026. PMID: 42492944. doi:10.1136/bmj-2026-100040
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。